3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
2360
Neoplasms
1709
Prostatic Neoplasms
1201
Lung Neoplasms
926
Colorectal Neoplasms
886
Carcinoma, Non-Small-Cell Lung
869
Leukemia, Myeloid, Acute
593
Pancreatic Neoplasms
578
Multiple Myeloma
551
Carcinoma, Hepatocellular
518
Brain Neoplasms
516
Neoplasm Metastasis
462
Head and Neck Neoplasms
458
Melanoma
417
Ovarian Neoplasms
414
Glioblastoma
403
Precursor Cell Lymphoblastic Leukemia-Lymphoma
400
Stomach Neoplasms
377
Uterine Cervical Neoplasms
365
Squamous Cell Carcinoma of Head and Neck
362
Rectal Neoplasms
342
Recurrence
337
Sarcoma
327
Hematologic Neoplasms
324
Colonic Neoplasms
323
Lymphoma
321
Triple Negative Breast Neoplasms
291
Carcinoma, Renal Cell
284
Glioma
283
Urinary Bladder Neoplasms
281
Interventions
ofatumumab
1
daratumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
×
1 year
×
Clear all
NCT06867991
2025-07-15
RADIA
The First People's Hospital of Changzhou
Phase 3
Recruiting
200 enrolled